UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
Rhea-AI Summary
UroGen (Nasdaq: URGN) entered an amended senior secured term loan with funds managed by Pharmakon on Feb 26, 2026, providing up to $250 million in two tranches.
The first tranche of $200 million funded at closing refinances an existing $125 million facility, sets a fixed 8.25% interest rate, allows a discretionary $50 million draw through June 30, 2027, has no financial covenants, and schedules repayment in four equal quarterly payments beginning Q1 2030.
Positive
- $200 million funded at closing to refinance existing debt and add non-dilutive capital
- Senior secured facility up to $250 million with an additional $50 million tranche available
- Fixed interest rate of 8.25% provides rate certainty
- No financial covenants, increasing near-term balance sheet flexibility
- Repayment deferred until Q1 2030, improving short-term liquidity profile
Negative
- Total available debt capacity increased from $125 million to $250 million, raising leverage potential
- Mandatory repayment in four equal quarterly payments starting Q1 2030 creates concentrated cash outflows
- Optional $50 million tranche, if drawn, will further increase debt on the balance sheet
News Market Reaction – URGN
On the day this news was published, URGN declined 12.35%, reflecting a significant negative market reaction. Argus tracked a trough of -20.3% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $143M from the company's valuation, bringing the market cap to $1.02B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
URGN’s positive move of 2.46% contrasts with mixed peers: names like SANA and SYRE are up modestly, while EYPT, OCS, and especially QURE (recent sharp decline) are down, pointing to a company-specific reaction to the refinancing rather than a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 27 | Clinical data update | Positive | +2.5% | Phase 3 ENVISION analyses showed strong ZUSDURI complete response durability. |
| Feb 24 | Conference presentation | Positive | -0.4% | Announcement of TD Cowen conference appearance with webcast and 1x1 meetings. |
| Feb 23 | Earnings date notice | Positive | -0.7% | Scheduled Q4 and full-year 2025 results with follow-up webcast and call. |
| Feb 04 | Conference presentation | Positive | +3.5% | Guggenheim biotech summit participation with webcast and investor meetings. |
| Jan 05 | Reimbursement update | Positive | -2.5% | Permanent J code J9282 for ZUSDURI effective, easing billing and access. |
Recent history shows mixed price reactions to largely positive news, with several instances of the stock declining on favorable updates, indicating inconsistent alignment between news tone and near-term price moves.
Over the past few months, UroGen has reported several constructive developments. Clinical data for ZUSDURI showed durable complete responses across EORTC risk groups, and a permanent J code J9282 became effective on January 1, 2026, supporting reimbursement. The company also remained visible at healthcare conferences and set expectations for its Q4 and full‑year 2025 results. Today’s refinancing announcement fits a pattern of steps aimed at strengthening the commercial and financial platform around its bladder cancer franchise.
Market Pulse Summary
The stock dropped -12.3% in the session following this news. A negative reaction despite this refinancing could fit URGN’s history of occasionally selling off on seemingly positive updates. The amended facility provides up to $250 million with a fixed 8.25% rate and repayments deferred until 2030, which may ease balance sheet pressures but also increases leverage. Some investors may focus on overall debt load or past insider sales tied to equity awards. If sentiment turns cautious on execution or growth, the refinancing alone may not support the stock.
Key Terms
senior secured term loan financial
non-dilutive capital financial
AI-generated analysis. Not financial advice.
Opportunistic refinancing meaningfully reduces cost of capital with
Additional
PRINCETON, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, announced it has entered into an agreement with funds managed by Pharmakon Advisors, LP (Pharmakon) to revise the terms of its loan agreement entered into in March 2024.
On February 26, 2026, the Company entered into an amended and restated loan agreement with funds managed by Pharmakon for a senior secured term loan of up to
“We are pleased to announce our expanded partnership with Pharmakon,” said Chris Degnan, Chief Financial Officer of UroGen. “This refinancing strengthens UroGen’s financial position by lowering our overall cost of capital, extending our maturity profile, and enhancing balance sheet flexibility. Importantly, it provides meaningful capital to support life-cycle management of our approved products and advancement of our pipeline. With a fixed interest rate and favorable long-dated maturity, this structure better positions UroGen to execute its long-term growth strategy and create value for both patients and shareholders.”
“Pharmakon is proud to continue supporting UroGen’s mission to address meaningful unmet needs in urothelial cancers,” said Martin Friedman, Principal at Pharmakon. “We have strong confidence in the company’s portfolio and commercial foundation, and this updated debt facility reflects our longstanding partnership and conviction in UroGen’s strategy as it enters its next phase of growth.”
TD Cowen acted as the exclusive financial advisor to UroGen on the transaction. Cooley LLP acted as legal advisor to UroGen. Akin Gump acted as legal advisor to Pharmakon.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and second product (mitomycin) for intravesical solution for patients with recurrent LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X, @UroGenPharma
About Pharmakon Advisors
Pharmakon Advisors, LP is a leading investor in non-dilutive debt for the life sciences industry and is the investment manager of the BioPharma Credit funds. Established in 2009, funds managed by Pharmakon Advisors, LP have committed up to
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the expected benefits of the amended and restated term loan agreement with Pharmakon, including its potential to strengthen UroGen’s financial position by lowering overall cost of capital, extending the maturity profile, enhancing balance sheet flexibility, and better positioning UroGen to execute on its long-term growth strategy; the potential of UroGen’s proprietary RTGel technology to improve therapeutic profiles of existing drugs, other than mitomycin; and UroGen’s sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as “anticipate,” “expect,” “may,” “potential,” “up to,” “will” or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: clinical results may not be indicative of results that may be observed in the future, including in larger populations; potential safety and other complications related to UroGen’s products; risks related to our and our licensors’ ability to protect our respective patents and other intellectual property; the ability to maintain regulatory approval; complications associated with commercialization activities; labeling limitations; competition in UroGen’s industry; the scope, progress and expansion of developing and commercializing UroGen’s products and product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures, such as surgery; UroGen’s ability to attract or retain key management, members of the board of directors and other personnel; UroGen’s RTGel technology and ZUSDURI may not perform as expected; new data relating to ZUSDURI, including from spontaneous adverse event reports and from the ongoing ENVISION trial, may result in changes to the product label and may adversely affect sales, or result in withdrawal of ZUSDURI from the market; the potential for payors to delay, limit or deny coverage for ZUSDURI; UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology; and the impacts of general macroeconomic and geopolitical conditions on UroGen’s business and financial position. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 6, 2025, as updated by the Risk Factors section of UroGen’s Annual Report on Form 10-K for the year ended December 31, 2025, being filed with the SEC today, the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.
INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083
FAQ
What are the key terms of UroGen's (URGN) refinanced loan agreement with Pharmakon announced March 2, 2026?
How and when will UroGen (URGN) repay the new Pharmakon term loan?
Does the UroGen (URGN) refinancing include financial covenants that could restrict operations?
What immediate financial impact does the $200 million closing tranche have for UroGen (URGN)?
What is the availability and deadline for UroGen (URGN) to draw the additional $50 million tranche?
